End of the line for Merck's TIGIT, LAG-3 cancer drugs

cafead

Administrator
Staff member
  • cafead   Dec 17, 2024 at 12:12: PM
via Merck has decided to abandon the development of its anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, blowing a hole in its immuno-oncology pipeline.

article source